Terns Pharmaceuticals (TERN) Financials

Terns Pharmaceuticals (NASDAQ: TERN) continues to operate as a development-stage biotech with no reported revenue in the most recent quarters and ongoing net losses. The company has largely funded its burn through equity financing in 2025, which has created a sizeable cash runway and a strong equity base on the balance sheet. However, this financing-driven path implies ongoing dilution risk for shareholders. Below are the 10 most material takeaways, with positive items first, then neutral, then negative.

• Massive 2025 equity raises supporting a large financing runway. Issuance of common equity in 2025 Q2 and again in 2025 Q4 totaled about $706.65 million each, contributing to net financing inflows around $743.12 million in those quarters. This funding dramatically offsets operating losses and funds ongoing development activities.
• Robust near-term cash runway. Cash and cash equivalents were about $150.7 million by Q3 2025, helped by the sizable financing inflows, providing a solid liquidity cushion for continued operations and R&D.
• Healthy equity base on the balance sheet. Total Common Equity sits in the mid-$284 million to $305 million range across 2025 (e.g., $305.2m in Q2 2025 and $284.1m in Q3 2025), indicating strong capitalization relative to liabilities.
• Low near-term liabilities relative to assets. Total Liabilities remained modest (e.g., around $17.6 million in Q3 2025; current liabilities around $15.4 million), suggesting a comfortable liquidity cushion given the asset base.
• Substantial asset base despite ongoing losses. Total Assets consistently sit in the $300–320 million range across 2025 quarters, underscoring a sizable asset base to support potential future financings or partnerships.
• No revenue in recent quarters (consistent with a pre-revenue development profile). Total Revenue reported as 0.0 in several periods, which is expected for a late-stage development company still building its pipeline.
• Total assets and liabilities show quarter-to-quarter fluctuation. Balance sheets in 2025 show asset levels in the $300–320 million range and current liabilities in the low tens of millions, reflecting normal quarterly variability rather than a clear trend.
• Ongoing quarterly net losses and negative operating performance. Net income attributable to common shareholders runs in the mid-$20s millions per quarter (e.g., -$23.6 million in Q3 2025 and -$23.6 million in Q4 2025), highlighting persistent losses during development.
• Continued cash burn from operations. Net cash from continuing operating activities has been negative in the high-teens to mid-$20s millions per quarter (e.g., about -$19.8 million in Q3 2025 and -$19.1 million in Q4 2025), indicating a need for ongoing external funding to sustain operations.
• Investing activity and dilution risk remain a concern. Large investing outflows in some quarters (notably significant purchases of investments) combined with equity financing raise dilution concerns for existing shareholders and suggest an uneven use of capital as development progresses.

In summary, Terns has funded substantial operating losses through large equity financings in 2025, creating a strong cash runway and a solid equity base. While this supports continued development, the company’s lack of revenue and reliance on dilutive financing, along with ongoing cash burn and investing outflows, indicate a high-risk, high-uncertainty path typical of development-stage biotech companies. Investors should watch for any inflection points such as revenue milestones, licensing deals, or partnerships that could reduce the need for further dilutive financings.